Shares of Hemostemix Inc. (CVE:HEM – Get Free Report) traded up 38.1% during trading on Thursday . The stock traded as high as C$0.15 and last traded at C$0.15. 605,625 shares were traded during mid-day trading, an increase of 51% from the average session volume of 401,760 shares. The stock had previously closed at C$0.11.
Hemostemix Stock Performance
The company has a market cap of C$12.63 million, a P/E ratio of -7.25 and a beta of 0.20. The business’s fifty day moving average is C$0.09 and its two-hundred day moving average is C$0.07.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Stories
- Five stocks we like better than Hemostemix
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- 3 Smart Picks: Discounted Stocks for Savvy Investors
- Energy and Oil Stocks Explained
- NVIDIA Deal Ignites Aurora Stock’s Explosive Potential
- Canada Bond Market Holiday: How to Invest and Trade
- Why AMD Stock Might Already Be This Year’s Best Buy
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
